1. 药时代DrugTimes首页
  2. BD PROJECTS
  3. Request for Product

【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications

• Request for Product

If your company is interested in this opportunity, please contact us as soon as possible!

浏览量 1136

【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications

【Project Code】BP-20240516-L-EE-108
【Demand Party】MNCs, major Chinese pharmaceutical companies, US biotech companies
【Disease Area】Metabolism
【Indications】Obesity, Overweight
【Target/MOA】ActRIIB Inhibitor
【Product Stage】PCC, Preclinical, Phase 1 Clinical
【Molecular Entity】All are considered
【Rights】Overseas rights (outside of China or the Greater China Region), Global rights
【Cooperation Mode】Licensing
海外权益！欧美biotech公司希望license帕金森病新药 |【药时代BD需求】
 

 

If your company is interested in this opportunity, please contact us as soon as possible!

Please indicate the project code (BP-20240516-L-EE-108).

We will discuss in detail with you. Thank you!

Contact person: Richard

Phone: 17821449819

WeChat: DrugTimes_BD

Email: BD@drugtimes.cn

发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权

打赏 为好文打赏 支持药时代 共创新未来！ 为好文打赏 支持药时代 共创新未来！
0
上一篇 2024年6月24日 13:50
下一篇 2024年6月24日 16:40

相关推荐

公众号
公众号
分享本页
返回顶部
快讯
BD
公众号
电话
邮箱